

References

- Belknap, R., Holland, D., Feng, Pei-Jean., et al. (2017). Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection a randomized trial. *Annals of Internal Medicine*, 167(10):689-697
- Borisov, A.S. Morris, S.B., Update of Recommendations for Use of Once-Weekly Isoniazid-Rifapentine Regimen to Treat Latent Mycobacterium tuberculosis Infection.(MMWR Vol. 67 No. 25). Georgia: U.S. Department of Health and Human Services.
- Centers for Disease Control and Prevention. (2011). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent mycobacterium tuberculosis infection. (MMWR Vol. 60 No. 48). Georgia: U.S. Department of Health and Human Services.
- Cruz AT, Starke JR. Safety and completion of a 4-month course of rifampicin for latent tuberculous infection in children. *Int J Tuberc Lung Dis*.2014 Sep;18(9):1057-61. doi: 10.5588/ijtld.14.0286.
- Diallo, T.M., Adjobimey M., (2018) Safety and Side Effects of Rifampin versus Isoniazid in Children. *The New England Journal of Medicine*, 379(5). 454-463
- Holland, D., Sanders, G., Hamilton, C., and Stout, J. (2011). Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection. *Public Library of Science ONE*, 6(7). E22276.
- Martinson, N., Barnes, G., Moulton, L., et al. (2011). New regimens to prevent tuberculosis in adults with HIV infection. *New England Journal of Medicine*, 365. 11-20.
- Menzies, D.M., Adjobimey, R., et al. (2018). Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. *The New England Journal of Medicine*, 379(5). 440-453
- Schechter, M., Zajdenverg, R., Falco, G., et al. (2006). Weekly rifapentine/isoniazid or daily rifampin/pyrazinamide for latent tuberculosis in household contacts. *American Journal of Respiratory Critical Care Medicine*, 173. 922-926.
- Sterling, T., Villarino, M., Borisov, A., et al. (2011). Three months of rifapentine and isoniazid for latent tuberculosis infection. *The New England Journal of Medicine*, 365(23). 2155-2166.
- Sterling, TR., Moro, RN., Borisov, AS., et al. (2015). Flu-like and other systemic drug reactions among persons receiving weekly rifapentine plus isoniazid or daily isoniazid for treatment of latent tuberculosis infection in the PREVENT tuberculosis study. *Clinical Infectious Diseases*, 61 (4). 527-535.
- Villarino, M., Scott N., Weis, S., et al. (2015). Treatment for preventing Tuberculosis in children and adolescents. *JAMA Pediatrics*, 169(3):247- 255.